Grace Therapeutics (GRCE) Exchange Rate Effect (2019 - 2023)
Grace Therapeutics (GRCE) posted Exchange Rate Effect of -$134000.0 for Q1 2023, down 144.08% sequentially from $304000.0 in Q4 2022, and down 151.94% YoY from $258000.0 in Q1 2022.
Grace Therapeutics (GRCE) Exchange Rate Effect (2019 - 2023) Analysis & Trends
Grace Therapeutics has reported Exchange Rate Effect for 5 years, with the latest figure at -$134000.0 in Q1 2023.
- Quarterly Exchange Rate Effect fell 151.94% year-over-year to -$134000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2022 was $392000.0 (up 104.58% YoY) and the FY2022 annual result came in at $127000.0, up 102.57% from the prior year.
- Exchange Rate Effect slipped to -$134000.0 in Q1 2023 per GRCE's latest filing, from $304000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $2.7 million in Q4 2020 and troughed at -$8.4 million in Q1 2021.
- A 5-year average of -$290937.5 and a median of $144500.0 in 2020 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2021 and 2022: Exchange Rate Effect tumbled 3217.72% in 2021, then surged 1316.0% in 2022.
- Over 5 years, Exchange Rate Effect stood at $345000.0 in 2019, then soared by 676.23% to $2.7 million in 2020, then sank by 100.93% to -$25000.0 in 2021, then soared by 1316.0% to $304000.0 in 2022, then sank by 144.08% to -$134000.0 in 2023.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered -$134000.0, $304000.0, and -$221000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -2.45 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -287,000.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.63 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -134,000.00 |
| Mar 31, 2023 | -134,000.00 |
| Dec 31, 2022 | 304,000.00 |
| Dec 31, 2022 | 304,000.00 |
| Sep 30, 2022 | -221,000.00 |
| Sep 30, 2022 | -221,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | 258,000.00 |
| Mar 31, 2022 | 258,000.00 |
| Dec 31, 2021 | -25,000.00 |
| Dec 31, 2021 | -25,000.00 |
| Sep 30, 2021 | -978,000.00 |
| Sep 30, 2021 | -978,000.00 |
| Jun 30, 2021 | 872,000.00 |
| Jun 30, 2021 | 872,000.00 |
| Mar 31, 2021 | -8.43 Mn |
| Mar 31, 2021 | -8.43 Mn |
| Dec 31, 2020 | 2.68 Mn |
| Dec 31, 2020 | 2.68 Mn |